

Article

# Genetic Variants at the 9p21.3 Locus Are Associated with Risk for Non-Compressible Artery Disease: Results from the ARTPER Study

Marc Via <sup>1,2,\*</sup>, Guillem Pera <sup>3</sup>, Rosa Forés <sup>3</sup>, Anna Costa-Garrido <sup>3</sup>, Antonio Heras <sup>3,4</sup>, José Miguel Baena-Díez <sup>5,6</sup>, Edurne Pedrosa <sup>7</sup>, Inmaculada C. Clemente <sup>1,2</sup>, Noemí Lamonja-Vicente <sup>3,8</sup>, Maria Mataró <sup>2,8</sup>, Pere Torán-Montserrat <sup>3</sup> and M. Teresa Alzamora <sup>3,4</sup>

- <sup>1</sup> Brainlab-Grup de Recerca en Neurociència Cognitiva, Departament de Psicologia Clínica i Psicobiologia, Institut de Neurociències, Universitat de Barcelona, 08035 Barcelona, Spain; iclemente@ub.edu
- <sup>2</sup> Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain; mmataro@ub.edu
- <sup>3</sup> Unitat de Suport a la Recerca Metropolitana Nord, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), 08303 Mataró, Spain; gpera@idiap.cat (G.P.); rosafores2011@gmail.com (R.F.); acostaga.mn.ics@gencat.cat (A.C.-G.); aheras.bnm.ics@gencat.cat (A.H.); noemilamonjavicente@gmail.com (N.L.-V.); ptoran.bnm.ics@gencat.cat (P.T.-M.); maiteal2007@gmail.com (M.T.A.)
- <sup>4</sup> Centre d'Atenció Primària Riu Nord-Riu Sud Santa Coloma de Gramenet, Direcció d'Atenció Primària Barcelonès Nord i Maresme, Institut Català de la Salut, 08921 Santa Coloma de Gramenet, Spain
- <sup>5</sup> Centre d'Atenció Primària la Marina, Direcció d'Atenció Primària Barcelona Ciutat, Institut Català de la Salut, 08038 Barcelona, Spain; josemibaena@gmail.com
- <sup>6</sup> Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), 08007 Barcelona, Spain
- <sup>7</sup> IGTP-HUGTP Biobank, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain; epedrosab@igtp.cat
- <sup>8</sup> Departament de Psicologia Clínica i Psicobiologia, Institut de Neurociències, Universitat de Barcelona, 08035 Barcelona, Spain
- \* Correspondence: mvia@ub.edu



**Citation:** Via, M.; Pera, G.; Forés, R.; Costa-Garrido, A.; Heras, A.; Baena-Díez, J.M.; Pedrosa, E.; Clemente, I.C.; Lamonja-Vicente, N.; Mataró, M.; et al. Genetic Variants at the 9p21.3 Locus Are Associated with Risk for Non-Compressible Artery Disease: Results from the ARTPER Study. *Genes* **2024**, *15*, 2. <https://doi.org/10.3390/genes15010002>

Academic Editor: David N. Cooper

Received: 14 November 2023

Revised: 10 December 2023

Accepted: 15 December 2023

Published: 19 December 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Peripheral artery disease (PAD) and non-compressible artery disease (NCAD) constitute predictors of subclinical atherosclerosis easily assessed through the ankle brachial index (ABI). Although both diseases show substantial genetic influences, few genetic association studies have focused on the ABI and PAD, and none have focused on NCAD. To overcome these limitations, we assessed the role of several candidate genes on the ABI, both in its continuous distribution and in the clinical manifestations associated to its extreme values: PAD and NCAD. We examined 13 candidate genomic regions in 1606 participants from the ARTPER study, a prospective population-based cohort, with the ABI assessed through ultrasonography. Association analyses were conducted independently for individuals with PAD (ABI < 0.9) or with NCAD (ABI > 1.4) vs. healthy participants. After including potential covariates and correction for multiple testing, minor alleles in the genetic markers rs10757278 and rs1333049, both in the 9p21.3 region, were significantly associated with a decreased risk of NCAD. Associations with the ABI showed limited support to these results. No significant associations were detected for PAD. The locus 9p21.3 constitutes the first genetic locus associated with NCAD, an assessment of subclinical atherosclerosis feasible for implementation in primary healthcare settings that has been systematically neglected from genetic studies.

**Keywords:** ankle brachial index; non-compressible artery disease; peripheral artery disease; 9p21.3; subclinical atherosclerosis

## 1. Introduction

Atherosclerotic cardiovascular diseases (CVDs) continue to be the main cause of death in developed countries, although mortality associated to them has decreased in most regions of the world in the last decades [1]. In the United States, they are estimated to

represent an economic burden of USD 11.3 trillion until 2050 [2]. Among other CVDs, peripheral artery disease (PAD) is a common manifestation of atherosclerosis characterized by a narrowing of peripheral arteries that increases cardiovascular and cerebrovascular morbid-mortality incidence [3]. Around the world, 202 million people have PAD. The prevalence of PAD [assessed as an ankle brachial index (ABI)  $< 0.9$ ] ranges from 3.7 to 7% in the general population of countries with a low cardiovascular risk [4,5] with an overall increase during the last decades. Worldwide, the prevalence of this disease has increased more than 17% between 2010 and 2015 [6]. Conversely, a high ABI (ABI  $\geq 1.4$ ) result indicates non-compressible artery disease (NCAD), suggesting the presence of arterial calcification in the lower limbs [7], and is also associated with an increased risk of morbid-mortality [8–10]. The prevalence of NCAD is 6.2% in the same population to which the present study refers [11] and is twice as frequent in males as in females. In this sense, the ABI constitutes a predictor of subclinical atherosclerosis feasible to be systematically assessed in primary healthcare settings.

The main factors associated to an increased risk of PAD are environmental factors also associated to atherosclerosis, especially smoking, age, sex, type 2 diabetes, dyslipidemia, hypertension, or obesity, among others. However, several studies indicate a remarkable genetic component in the etiology of PAD. A family history of PAD and its clinical symptoms have been identified as independent risk factors for PAD [12,13], indicating a role for genetic or shared environmental factors. Moreover, twin studies have estimated that 58% and 48% of the observed variability in PAD and in ABI values, respectively, could be attributed to additive genetic effects [14,15]. Estimates of genetic influences for arterial calcification have yielded similar results, with heritability values ranging between 42 and 51% depending on the study and the type of calcification analyzed, although only abdominal aortic and coronary atherosclerotic calcification (CAC) have been examined (reviewed in [16]).

Despite this important genetic component, the specific genetic variants involved in pathological ABI values remain elusive. In contrast to thousands of association studies for other atherosclerotic pathologies, such as coronary artery disease or stroke, few reports on the ABI and PAD, and none on NCAD, have been published. For years, studies on the genetic bases of PAD used a candidate gene approach and focused on pathways relevant in atherosclerosis, such as lipid metabolism, endothelial function, or inflammation, among others. However, a meta-analysis from the candidate gene association resource (CARE) consortium for PAD and continuous ABI did not identify any robust association after examining 11 different studies [17]. With the advent of genotyping array technologies, several genome-wide association studies (GWASs) were conducted without a clear consensus on their findings. A meta-analysis of 21 GWASs published in 2012 only identified one genome-wide significant locus (9p21.3) with the ABI and none with categorical PAD [18]. There has not been much advance in the genetics of PAD until two recent efforts, which have shed some light on the genetic determinants of PAD by combining data from hundreds of thousands of individuals. Klarin and colleagues identified 19 loci associated with PAD in the Million Veteran Program (MVP) and the UK Biobank datasets [19], and a genome-wide meta-analysis just confirmed five of these associations in an independent sample of 449,548 individuals (12,086 PAD cases) [20]. One of these studies also included ABI data in the analyses, and locus 9p21.3 was the only genome-wide significant region associated with continuous ABI [19].

No previous studies have examined genetic determinants of NCAD assessed through the ABI. Moreover, genetic studies on the ABI have actively excluded individuals with values higher than 1.4 from their analyses (e.g., [17–19]). As for arterial calcification, some studies have focused on coronary artery calcification (CAC), another marker of subclinical atherosclerosis. In this sense, the most comprehensive meta-analysis of genome-wide association studies for CAC identified 11 independent risk loci as influencing CAC [21]. In addition, different association studies have screened the implication of specific candidate genes on arterial calcification revealing promising markers in specific pathways such as endothelial function, cell adhesion, and extracellular matrix remodeling (as a review, see [16]).

In the present study, we aimed at clarifying the relationship between variants in several candidate genes and differences in the ABI, both in its continuous distribution and in the clinical manifestations associated to its extreme values: PAD and NCAD. To do so, we explored fifteen genetic markers in candidate regions in the well-characterized subjects of the population-based Peripheral Arterial Disease (PERART/ARTPER) study. These candidate regions include regions previously associated to the ABI and genes associated to other atherosclerotic pathologies but not specifically tested for PAD or NCAD.

## 2. Materials and Methods

### 2.1. Subjects

A detailed description of the ARTPER study has been published previously [4,22]. Briefly, the ARTPER study is an ongoing prospective, multicenter, population-based cohort of 3786 subjects older than 49 years with the aim of determining the prevalence of peripheral artery disease and related cardiovascular risk factors in the general population. Individuals were recruited between 2006 and 2008, with periodic phone and in situ follow-up interviews. Later, between 2011–2012, 1810 participants provided a blood sample to be used in genetic studies.

The study was approved by the local ethical review board (IDIAP Jordi Gol Foundation of Investigation in Primary Care (P11/61)), and all participants provided written informed consent. Moreover, the recommendations of the World Medical Association Declaration of Helsinki were followed.

### 2.2. Data Collection

The determination of the ankle brachial index (ABI) of the participants was carried under standardized conditions by two trained healthcare professionals using a standardized Doppler Ultrasonic device (Mini-Dopplex D 900-P, Huntleigh Healthcare, 8 MHz). A detailed description of the procedure has been previously published [4]. A threshold of an ABI < 0.9 was used to define PAD since it presents a high sensitivity and specificity for the detection of stenosis  $\geq 50\%$  in peripheral arteries [23,24]. Conversely, an ABI  $\geq 1.4$  was used to define the presence of calcification (NCAD) in the peripheral arteries [9].

A comprehensive questionnaire collected demographic, clinical, and lifestyle variables, including smoking status, physical activity, previous cardiovascular pathology (self-reported and in the clinical history), anthropometric measurements (height, weight, and waist circumference), hypertension, diabetes mellitus, and blood test results (total cholesterol, HDL-cholesterol, triglycerides, and glycemia), among others. The demographic and clinical characteristics of the final sample are described in Table 1.

**Table 1.** Demographic and clinical characteristics of participants. Data are presented as mean (SD) for continuous variables and as absolute (%) frequencies for binary variables.

|                                       | Controls<br>(0.9 < ABI < 1.4) | PAD<br>(ABI < 0.9) | NCAD<br>(ABI $\geq 1.4$ ) |
|---------------------------------------|-------------------------------|--------------------|---------------------------|
| N                                     | 1367                          | 112                | 127                       |
| Age                                   | 67.9 (7.6)                    | 72.5 (8.3) ***     | 70.2 (8.0) **             |
| Male sex                              | 567 (41%)                     | 66 (59%) ***       | 86 (68%) ***              |
| Cardiovascular pathology <sup>1</sup> | 146 (11%)                     | 40 (36%) ***       | 17 (13%)                  |
| Hypertension                          | 756 (55%)                     | 86 (77%) ***       | 72 (57%)                  |
| Diabetes                              | 276 (20%)                     | 42 (38%) ***       | 36 (28%) *                |
| Dyslipidemia                          | 878 (64%)                     | 84 (75%) *         | 81 (64%)                  |
| BMI                                   | 29.3 (4.6)                    | 29.8 (4.87)        | 30.38 (4.7) *             |
| Abdominal obesity <sup>2</sup>        | 850 (63%)                     | 71 (64%)           | 81 (64%)                  |
| Ever smoker                           | 591 (43%)                     | 73 (65%) ***       | 66 (52%)                  |
| Physical activity <sup>3</sup>        | 6982 (4828)                   | 5402 (3869) ***    | 7278 (5605)               |

<sup>1</sup> Cardiovascular pathology defined as AIM, angina, stroke, or TIA. <sup>2</sup> Abdominal obesity defined as waist circumference  $\geq 102/88$  cm (male/female). <sup>3</sup> Physical activity defined as METS expenditure in 14 days performing leisure activity (walking, sport, shopping, cleaning, or gardening). \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ , in the comparisons with controls using Student's *t* and chi-square tests for continuous and binary variables, respectively.

### 2.3. Genetic Analyses

Genomic DNA was isolated from the whole peripheral blood by automated DNA purification based into M-PVA Magnetic Bead Technology using the Chemagic Magnetic Separation Module I instrument (Revvity, Inc., Waltham, MA, USA) at the IGTP-HUGTP Biobank (Spanish National Registry of Biobanks B.0000643) integrated in the Platform ISCIII Biobanks and Biomodels (PT20/00050). We determined DNA quality by the absorbance method. The 260/230 nm ratio was 1.7–2.1, and the 260/280 nm ratio was higher, 1.8, demonstrating a good DNA accuracy. Samples were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committees.

Fifteen single-nucleotide polymorphisms (SNPs) in 13 different chromosomal regions were genotyped using KASPar assays, an allele-specific PCR technology, by an external genotyping core facility (Progenika Biopharma S.A., Derio, Spain). SNPs were selected based on two criteria: location in a gene or chromosomal region previously associated with PAD or with other related cardiovascular phenotypes and a minor allele frequency (MAF) higher than 10% in the Iberian population from the 1000 Genomes Project (except for the polymorphisms in the *APOE* gene) to maximize statistical power to detect genetic effects [25]. These included markers in gene regions involved in endothelial function, inflammation and immunity, or lipid metabolism, among other pathways. Details on the selected SNPs (identifier, chromosomal location, MAF, etc.) are described in Table 2.

### 2.4. Statistical Analyses

Quality control (QC) analyses were performed on the dataset. Forty-one negative controls and nine positive controls (i.e., sample duplicates) were included. Missingness by individual and by marker and deviations from Hardy–Weinberg equilibrium expectations were assessed to check data quality. After QC, the potential presence of population stratification effects between cases and controls was assessed through the calculation of the inflation factor ( $\lambda$ ).

Association analyses were conducted by means of logistic regression models for binary traits (i.e., PAD and NCAD) and by linear regression models for continuous variables (i.e., ABI). All analyses compared, in different models, individuals with PAD or with NCAD vs. healthy participants. The analyses estimated effect sizes (odds ratio (OR) or  $\beta$  ( $\beta$ ) for logistic and linear regressions, respectively) with their 95% confidence intervals under an additive genetic model. The analyses were conducted without covariates (unadjusted) and including all potential covariates identified in previous studies as influencing the ABI and PAD: sex, age, cardiovascular pathology, hypertension, diabetes, dyslipidemia, smoking, physical activity, central obesity, and abdominal obesity. Significant results were further evaluated under different models of genetic effect (i.e., dominant and recessive) in an attempt to clarify biological effects. To correct the rate of type I error, a false discovery rate (FDR) controlling procedure and a permutation test (1000 permutations) were implemented on significant results. The linkage disequilibrium was quantified between the markers in the 9p21.3 chromosomal region. All QC and association analyses were conducted using PLINK v.1.9 (<https://www.cog-genomics.org/plink/1.9/> (accessed on 7 October 2019) [26]), specific for genetic association analyses.

Finally, we used the software QUANTO v.1.2.4 to estimate the minimum size of genetic effect that our cohort has statistical power to detect [27] (<https://preventivemedicine.usc.edu/download-quanto/> (accessed on 15 September 2019)). We run post hoc power calculations based on our sample size and the minor allele frequency of the included SNPs and assuming additive effects, a statistical power of 80%, and a two-sided significance threshold of 0.05. Power calculations for the ABI as a quantitative outcome used a mean value of 1.039 and an SD of 0.130.

**Table 2.** Logistic regression results on PAD. Adjusted models included as covariates: age, sex, cardiovascular pathology, hypertension, diabetes, dyslipidemia, smoking, physical activity, central obesity, and abdominal obesity. A1/A2: minor/major allele; MAF: minor allele frequency; L95/U95: lower/upper bounds of the 95% confidence interval. Analyses were conducted under an additive model.

| Gene/Locus     | Chr | SNP        | Position  | A1 | A2 | MAF  | n    | Unadjusted Model |      |      |          | n    | Adjusted Model |      |      |          |
|----------------|-----|------------|-----------|----|----|------|------|------------------|------|------|----------|------|----------------|------|------|----------|
|                |     |            |           |    |    |      |      | OR               | L95  | U95  | <i>p</i> |      | OR             | L95  | U95  | <i>p</i> |
| <i>TNFRSF9</i> | 1   | rs2453021  | 7929506   | A  | G  | 0.36 | 1473 | 0.97             | 0.72 | 1.29 | 0.809    | 1388 | 1.11           | 0.81 | 1.51 | 0.507    |
| <i>MTHFR</i>   | 1   | rs1801133  | 11796321  | T  | C  | 0.41 | 1476 | 0.97             | 0.73 | 1.28 | 0.819    | 1390 | 0.81           | 0.60 | 1.11 | 0.190    |
| <i>OSBPL10</i> | 3   | rs1902341  | 31754078  | A  | G  | 0.42 | 1474 | 0.97             | 0.73 | 1.28 | 0.808    | 1388 | 0.98           | 0.73 | 1.33 | 0.915    |
| <i>VEGF-A</i>  | 6   | rs699947   | 43768652  | A  | C  | 0.47 | 1477 | 0.81             | 0.62 | 1.07 | 0.134    | 1391 | 0.82           | 0.61 | 1.10 | 0.176    |
| <i>IL6</i>     | 7   | rs1800795  | 22727026  | C  | G  | 0.35 | 1472 | 1.18             | 0.88 | 1.56 | 0.266    | 1387 | 1.17           | 0.86 | 1.59 | 0.317    |
| 9p21.3         | 9   | rs10757278 | 22124478  | A  | G  | 0.48 | 1451 | 0.85             | 0.64 | 1.11 | 0.228    | 1366 | 0.91           | 0.68 | 1.22 | 0.516    |
| 9p21.3         | 9   | rs1333049  | 22125504  | G  | C  | 0.48 | 1473 | 0.82             | 0.63 | 1.08 | 0.155    | 1387 | 0.86           | 0.64 | 1.16 | 0.330    |
| <i>BDNF</i>    | 11  | rs6265     | 27658369  | T  | C  | 0.22 | 1478 | 1.01             | 0.73 | 1.41 | 0.951    | 1392 | 1.04           | 0.73 | 1.48 | 0.845    |
| <i>MMP1</i>    | 11  | rs1799750  | 102799765 | G  | T  | 0.50 | 1470 | 1.03             | 0.79 | 1.36 | 0.822    | 1384 | 1.07           | 0.80 | 1.45 | 0.640    |
| <i>MMP3</i>    | 11  | rs35068180 | 102845216 | C  | A  | 0.47 | 1467 | 0.81             | 0.62 | 1.07 | 0.144    | 1382 | 0.79           | 0.58 | 1.07 | 0.126    |
| <i>CCL2</i>    | 17  | rs1024611  | 34252769  | G  | A  | 0.23 | 1471 | 1.15             | 0.84 | 1.58 | 0.381    | 1386 | 1.10           | 0.78 | 1.55 | 0.573    |
| <i>CCL5</i>    | 17  | rs2107538  | 35880776  | T  | C  | 0.17 | 1476 | 0.94             | 0.65 | 1.37 | 0.759    | 1390 | 0.94           | 0.63 | 1.40 | 0.772    |
| <i>ICAM-1</i>  | 19  | rs5498     | 10285007  | G  | A  | 0.50 | 1474 | 0.79             | 0.60 | 1.04 | 0.093    | 1388 | 0.78           | 0.57 | 1.06 | 0.107    |
| <i>APOE</i>    | 19  | rs429358   | 44908684  | C  | T  | 0.10 | 1465 | 0.79             | 0.48 | 1.30 | 0.357    | 1380 | 0.73           | 0.43 | 1.25 | 0.252    |
| <i>APOE</i>    | 19  | rs7412     | 44908822  | T  | C  | 0.05 | 1473 | 0.77             | 0.39 | 1.51 | 0.442    | 1387 | 0.81           | 0.39 | 1.69 | 0.568    |

### 3. Results

#### 3.1. Sample

From the original 1810 subject dataset, 58 samples were removed for low quality of genetic results, and 4 samples presented low call rate and were also removed. All genetic markers fit Hardy–Weinberg equilibrium expectations ( $p > 0.1$ ), and all 50 controls (both positive and negative) were successfully identified. After quality control filters, genetic data for 1748 individuals were included, and the genotyping call rate was  $>99\%$ .

Subsequently, 119 subjects were removed because of discrepancies in data. Twenty-three subjects declared non-European ancestry and were not included to avoid potential population stratification effects in the study. Thus, the final sample included 1606 participants: 112 subjects with PAD (ABI  $< 0.9$ ), 127 with arterial calcification (ABI  $> 1.4$ ), and 1367 healthy controls ( $0.9 < \text{ABI} < 1.4$ ) (Table 1).

We did not detect signs of population stratification in our analyses, as estimated by inflation factors ( $\lambda$ ) lower than 1.1 ( $\lambda$  of 1.00 and 1.08 for the adjusted and unadjusted analyses, respectively). Power calculations estimated that our cohort was powered to identify alleles than conferred increases in the risk of developing PAD or NCAD (GRR) higher than 1.40–1.43 and increases in ABI higher than 0.010–0.014 units, depending on the minor allele frequency of the analyzed SNPs.

#### 3.2. Association Analyses

We did not find any significant association between the analyzed genetic variants and PAD (Table 2). Moreover, association analyses on the PAD severity, assessed as mild, moderate, or severe PAD (ABI values of 0.7–0.9, 0.4–0.7, and  $<0.4$ , respectively [13]), did not find significant associations. In contrast, polymorphisms in the 9p21.3 chromosomal region were significantly associated with the presence of calcified arteries in the lower limbs (Table 3). Minor alleles in SNPs rs10757278 and rs1333049 were significantly associated with a decreased risk of NCAD both in the unadjusted regression models and in the models adjusted for all covariates ( $p < 0.01$  in all cases). Given the differences across groups for some environmental risk factors (Table 1), we further explored if the exclusion of some covariates, specifically cardiovascular pathology and hypertension, from the adjusted models modified the observations, but the association results remained very stable across adjusted, unadjusted, and different partially adjusted models.

In the post hoc analyses, we analyzed different genetic models to clarify the biological mechanism of the observed associations. Thus, we detected a higher degree of association between variants in 9p21.3 and NCAD under a recessive genetic model (results shown in Table 4), but there were not associations under a dominant model ( $p > 0.10$ ).

**Table 3.** Logistic regression results on NCAD. Adjusted models included as covariates: age, sex, cardiovascular pathology, hypertension, diabetes, dyslipidemia, smoking, physical activity, central obesity, and abdominal obesity. A1/A2: minor/major allele; L95/U95: lower/upper bounds of the 95% confidence interval. Analyses were conducted under an additive model.

| Gene/Locus     | SNP        | A1 | A2 | n    | Unadjusted Model |      |      |       | p | n    | Adjusted Model |      |      |       |
|----------------|------------|----|----|------|------------------|------|------|-------|---|------|----------------|------|------|-------|
|                |            |    |    |      | OR               | L95  | U95  |       |   |      | OR             | L95  | U95  | p     |
| <i>TNFRSF9</i> | rs2453021  | A  | G  | 1486 | 1.02             | 0.77 | 1.33 | 0.912 |   | 1467 | 1.06           | 0.80 | 1.41 | 0.700 |
| <i>MTHFR</i>   | rs1801133  | T  | C  | 1490 | 0.93             | 0.71 | 1.22 | 0.602 |   | 1469 | 0.95           | 0.72 | 1.24 | 0.690 |
| <i>OSBPL10</i> | rs1902341  | A  | G  | 1488 | 1.04             | 0.80 | 1.36 | 0.761 |   | 1467 | 0.99           | 0.75 | 1.30 | 0.934 |
| <i>VEGF-A</i>  | rs699947   | A  | C  | 1492 | 0.92             | 0.72 | 1.19 | 0.536 |   | 1471 | 0.95           | 0.73 | 1.24 | 0.725 |
| <i>IL6</i>     | rs1800795  | C  | G  | 1486 | 0.91             | 0.68 | 1.20 | 0.483 |   | 1465 | 0.92           | 0.69 | 1.23 | 0.560 |
| 9p21.3         | rs10757278 | A  | G  | 1467 | 0.70             | 0.54 | 0.91 | 0.007 |   | 1446 | 0.69           | 0.53 | 0.91 | 0.008 |
| 9p21.3         | rs1333049  | G  | C  | 1487 | 0.69             | 0.53 | 0.90 | 0.006 |   | 1466 | 0.69           | 0.53 | 0.91 | 0.009 |
| <i>BDNF</i>    | rs6265     | T  | C  | 1493 | 1.24             | 0.92 | 1.67 | 0.157 |   | 1472 | 1.20           | 0.88 | 1.63 | 0.261 |
| <i>MMP1</i>    | rs1799750  | G  | -  | 1485 | 1.27             | 0.98 | 1.64 | 0.074 |   | 1464 | 1.28           | 0.98 | 1.68 | 0.068 |
| <i>MMP3</i>    | rs35068180 | -  | A  | 1481 | 1.02             | 0.79 | 1.33 | 0.870 |   | 1461 | 0.98           | 0.74 | 1.28 | 0.861 |
| <i>CCL2</i>    | rs1024611  | G  | A  | 1485 | 0.81             | 0.59 | 1.12 | 0.208 |   | 1464 | 0.83           | 0.59 | 1.16 | 0.269 |
| <i>CCL5</i>    | rs2107538  | T  | C  | 1492 | 0.94             | 0.66 | 1.32 | 0.705 |   | 1471 | 0.94           | 0.65 | 1.34 | 0.713 |
| <i>ICAM-1</i>  | rs5498     | G  | A  | 1489 | 0.85             | 0.65 | 1.10 | 0.223 |   | 1468 | 0.84           | 0.64 | 1.10 | 0.201 |
| <i>APOE</i>    | rs429358   | C  | T  | 1481 | 0.65             | 0.39 | 1.07 | 0.091 |   | 1460 | 0.66           | 0.40 | 1.11 | 0.116 |
| <i>APOE</i>    | rs7412     | T  | C  | 1488 | 0.83             | 0.44 | 1.54 | 0.544 |   | 1467 | 0.84           | 0.44 | 1.62 | 0.598 |

**Table 4.** Post hoc analyses under a recessive genetic model of associations between 9p21.3 markers and NCAD and ABI between NCAD and controls. Adjusted models included as covariates: age, sex, cardiovascular pathology, hypertension, diabetes, dyslipidemia, smoking, physical activity, central obesity, and abdominal obesity. A1/A2: minor/major allele; MAF: minor allele frequency; L95/U95: lower/upper bounds of the 95% confidence interval.

| NCAD       |            | A1 | A2 | MAF  | n    | Unadjusted Model |        |        |              | p | n    | Adjusted Model |        |       |              |
|------------|------------|----|----|------|------|------------------|--------|--------|--------------|---|------|----------------|--------|-------|--------------|
| Gene/Locus | SNP        |    |    |      |      | OR               | L95    | U95    |              |   |      | OR             | L95    | U95   | p            |
| 9p21.3     | rs10757278 | A  | G  | 0.48 | 1467 | 0.45             | 0.26   | 0.77   | <b>0.004</b> |   | 1446 | 0.47           | 0.27   | 0.81  | <b>0.007</b> |
| 9p21.3     | rs1333049  | G  | C  | 0.48 | 1487 | 0.45             | 0.26   | 0.78   | <b>0.004</b> |   | 1466 | 0.47           | 0.27   | 0.81  | <b>0.007</b> |
| ABI        |            | A1 | A2 | MAF  | n    | Unadjusted Model |        |        |              | p | n    | Adjusted Model |        |       |              |
| Gene/Locus | SNP        |    |    |      |      | β                | L95    | U95    |              |   |      | β              | L95    | U95   | p            |
| 9p21.3     | rs10757278 | A  | G  | 0.48 | 1467 | −0.012           | −0.024 | −0.001 | <b>0.040</b> |   | 1446 | −0.012         | −0.023 | 0.000 | 0.053        |
| 9p21.3     | rs1333049  | G  | C  | 0.48 | 1487 | −0.009           | −0.020 | 0.002  | 0.110        |   | 1466 | −0.008         | −0.020 | 0.003 | 0.149        |



Individuals carrying two minor alleles in any of the SNPs explored in locus 9p21.3 had less than half the risk of presenting calcified arteries either under an unadjusted model (OR = 0.45; 95%CI = 0.26/0.77;  $p = 0.004$ ) or after adjusting for all potential confounding variables (OR = 0.47; 95%CI = 0.27/0.81;  $p = 0.007$ ). The unadjusted models resisted both a correction for multiple comparisons using an FDR method ( $p = 0.029$ ) and a permutation test ( $p = 0.036$ – $0.038$ ), but the adjusted models only resisted the FDR control ( $p = 0.049$ ) and not the permutation test ( $p = 0.085$ ).

Association analyses of ABI as a continuous variable showed limited support to the results found in the analyses of binary traits. Under an additive model, no associations were identified between SNPs in the candidate genes and ABI neither when we analyzed individuals with PAD and controls nor among individuals with NCAD and controls (Supplementary Tables S1 and S2). We further conducted an association test between ABI and SNPs in the 9p21.3 region under a recessive genetic model since those were the analyses that showed the highest degree of association with arterial calcification (Table 4). Only SNP rs10757278 was associated with ABI at the standard nominal threshold ( $p = 0.040$  in an unadjusted model and  $p = 0.053$  in an adjusted model), with carriers of two copies of the minor allele (A) showing a lower ABI ( $\beta = -0.012$ ; 95%CI:  $-0.024/-0.001$ ). However, none of the comparisons held a correction for multiple comparisons or a permutation test ( $p > 0.3$  in all cases).

#### 4. Discussion

In this study, we analyzed fifteen polymorphic markers in 13 different genomic regions to identify genetic factors modulating the ABI, a well-known prognostic marker of CVD, and the risk to develop PAD or NCAD. We found that genetic variants at the 9p21.3 chromosomal region are significantly associated with an increased risk of NCAD in what constitutes, to our knowledge, the first genetic locus associated with arterial calcification assessed through ABI.

There is a broad consensus that ABI values higher than 1.4 are good predictors of subclinical atherosclerosis and cardiovascular risk assessment [7]. Other assessments of CV risk, such as CAC, may provide slightly better discrimination of risk, but its routine assessment is not feasible in primary healthcare settings since it is quantified through computed tomography [28,29]. Quick and non-invasive estimators of subclinical atherosclerosis, such as ABI, constitute practical alternatives to be implemented in primary care centers. However, clinical investigations on this complex phenotype have been limited compared with other CVD markers. Moreover, research on its genetic determinants has focused only on the lower tail of the distribution of ABI values, clinically associated to PAD, while systematically ignoring high values, associated to NCAD.

In our study, we conducted separate analyses for both tails of the distribution of ABI values. Thus, we found a remarkable protective effect of the minor allele at both SNPs in the 9p21.3 region (rs10757278-A and rs1333049-G), which are in tight linkage disequilibrium. Homozygotes for the minor allele at any of these two polymorphisms, which account for almost a quarter of our population, showed a risk of developing NCAD that was 40–110% lower than carriers of major alleles (OR = 0.69 and 0.46 for the minor allele under additive and recessive models, respectively).

Chromosome 9p21.3 harbors no known protein-coding genes, but it expresses a long noncoding RNA called *ANRIL* (antisense noncoding RNA in the *INK4* locus) that regulates genes in the atherogenic network [30]. Among other processes, *ANRIL* participates in the process of phenotypic switching of vascular smooth muscle cells to an adverse proliferative phenotype via microRNAs and the RAS/RAF/ERK signaling pathway (for a recent review, check [31]). The involvement of genetic variants at the 9p21.3 region in the pathophysiology of CVD was first identified by three independent GWASs in 2007 and has since been implicated in other CVD complications such as stroke or aneurysms. In this sense, our results extend to NCAD previous evidence on the implication of this chromosomal region in other endophenotypes of subclinical atherosclerosis, such as the ABI [18,19] and CAC [21].



This novel association, however, cannot be discussed with other reports on the genetics of NCAD, since the present work constitutes the first study published on the topic. So far studies have mostly focused on PAD as a binary outcome, and the few reports that have analyzed genetic determinants of the ABI as a continuous trait have actively excluded individuals with ABI > 1.4 from the analyses to remove heterogeneity from the analyses (e.g., [17–19]).

In contrast to coronary heart disease (CHD), very few genetic variants that influence susceptibility to PAD or ABI had been discovered until two recent genome-wide meta-analyses slightly broadened the list of associated loci [19,20]. Summarizing those and other previous works, the only locus that has been consistently associated with both PAD and ABI (limited to values lower than 1.4) is 9p21.3. In our study, we did not find any association between the markers in 9p21.3 or in any of the other 12 genomic regions analyzed and the risk to develop PAD or variation in ABI values. At most, a marginally significant association was observed between an SNP in the 9p21.3 region and ABI values among individuals with NCAD and controls but only under a recessive genetic model, the one with the strongest association with NCAD. Some of the difficulties identifying genetic factors associated to PAD and ABI might be attributed to the lower number of studies invested in the peripheral system and limited sample sizes, until some recent efforts. However, some authors have postulated that it might be also partly due to a greater degree of clinical and genetic heterogeneity in PAD [32]. In this sense, subdivision of precise phenotypes has been proposed as an approach to reduce heterogeneity and identify genetic markers that confer susceptibility to subclinical atherosclerosis [16]. The ABI can be considered an especially sensitive assessment of subclinical atherosclerosis since values at both extremes of its distribution are associated to different clinical manifestations: PAD and NCAD. This characteristic also implies that it needs special heed from an analytical point of view compared with other clinical measurements. Thus, a practical (but limited) approach has led researchers to remove high values from the analyses and focus only on PAD. Here we showed that separate analyses at both extremes of ABI values provide additional information on two different clinical entities related to subclinical atherosclerosis.

Other limitations of our study include the lack of a replication cohort to confirm our findings. Moreover, our analyses focused only on a restricted number of candidate genes instead of a genome-wide design, and thus, our conclusions were limited to a hypothesis-driven approach. Finally, our sample size had limited statistical power to detect small size effects, which tend to be the most common in genetic association studies of complex phenotypes, such as the ABI. Research in the field is starting to overcome this limitation by analyzing data from big cohorts, such as the UK Biobank or the MVP, but has also to be extended into generating joint consortia efforts, especially if multi-omics approaches are going to be implemented. In this sense, promising approaches to understand the pathophysiology of arterial calcification should consider the inclusion of system biology approaches combining at least epigenetic and genetic analyses. In the case of 9p21.3, for example, this locus exerts its functions through the expression of a non-coding RNA, which in turn is regulated by DNA methylation at the promoter region and by existing alleles [31]. Moreover, increasing evidence offers support for a relevant role of specific microRNAs in the pathophysiology, but also as diagnostic tools, of arterial calcification, PAD, and other atherosclerotic complications [33,34].

**Supplementary Materials:** The following supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/genes15010002/s1>: Table S1: Linear regression results on the ankle brachial index (ABI) in PAD and control individuals; Table S2: Linear regression results on the ankle brachial index (ABI) in NCAD and controls.

**Author Contributions:** Conceptualization, M.V., M.M., P.T.-M. and M.T.A.; formal analysis, M.V., G.P. and N.L.-V.; investigation, I.C.C. and E.P.; resources, E.P.; data curation, R.F., A.H. and J.M.B.-D.; writing—original draft preparation, M.V. and G.P.; writing—review and editing, M.V., G.P. and M.T.A.; visualization, A.C.-G.; supervision, M.V. and M.T.A.; funding acquisition, M.T.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Carlos III Institute of Health, Ministry of Economy and Competitiveness (Spain), co-funded with the European Union ERDF funds, grant numbers PI11/00765 and PT20/00050. This work was partially supported by ICREA under the ICREA Academia program to M.M.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the IDIAP Jordi Gol Foundation of Investigation in Primary Care (P11/61).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to consent limitations.

**Acknowledgments:** The study group would like to thank all the members of the ARTPER cohort for their participation in the study. We also would like to thank the editor and three anonymous reviewers for their contributions to improve the quality of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

## References

1. Moran, A.E.; Forouzanfar, M.H.; Roth, G.A.; Mensah, G.A.; Ezzati, M.; Murray, C.J.L.; Naghavi, M. Temporal Trends in Ischemic Heart Disease Mortality in 21 World Regions, 1980 to 2010. *Circulation* **2014**, *129*, 1483–1492. [[CrossRef](#)] [[PubMed](#)]
2. Chen, S.; Kuhn, M.; Prettnner, K.; Bloom, D.E. The Macroeconomic Burden of Noncommunicable Diseases in the United States: Estimates and Projections. *PLoS ONE* **2018**, *13*, e0206702. [[CrossRef](#)] [[PubMed](#)]
3. Shu, J.; Santulli, G. Update on peripheral artery disease: Epidemiology and evidence-based facts. *Atherosclerosis* **2018**, *275*, 379–381. [[CrossRef](#)] [[PubMed](#)]
4. Alzamora, M.T.; Forés, R.; Baena-Díez, J.M.; Pera, G.; Toran, P.; Sorribes, M.; Vicheto, M.; Reina, M.D.; Sancho, A.; Albaladejo, C.; et al. The Peripheral Arterial Disease Study (PERART/ARTPER): Prevalence and Risk Factors in the General Population. *BMC Public Health* **2010**, *10*, 38. [[CrossRef](#)]
5. Forés, R.; Alzamora, M.T.; Boixadera-Planas, E.; Vázquez, A.; Pera, G.; Torán, P. Evolución de la prevalencia de arteriopatía periférica en la práctica clínica: Estudio descriptivo poblacional con bases de datos reales (SIDIP-CMBD) [Evolution of the prevalence of peripheral artery disease in clinical practice: A descriptive population study with real databases (SIDIP-CMBD)]. *Aten. Primaria* **2022**, *54*, 102437. [[CrossRef](#)]
6. Song, P.; Rudan, D.; Zhu, Y.; Fowkes, F.J.L.; Rahimi, K.; Fowkes, F.G.R.; Rudan, I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: An updated systematic review and analysis. *Lancet Glob. Health* **2019**, *7*, e1020–e1030. [[CrossRef](#)]
7. Aboyans, V.; Criqui, M.H.; Abraham, P.; Allison, M.A.; Creager, M.A.; Diehm, C.; Fowkes, F.G.R.; Hiatt, W.R.; Jönsson, B.; Lacroix, P.; et al. Measurement and Interpretation of the Ankle-Brachial Index: A Scientific Statement from the American Heart Association. *Circulation* **2012**, *126*, 2890–2909. [[CrossRef](#)]
8. Nishimura, H.; Miura, T.; Minamisawa, M.; Ueki, Y.; Abe, N.; Hashizume, N.; Mochidome, T.; Harada, M.; Shimizu, K.; Shoin, W.; et al. Clinical Characteristics and Outcomes of Patients with High Ankle-Brachial Index from the IMPACT-ABI Study. *PLoS ONE* **2016**, *11*, e0167150. [[CrossRef](#)]
9. Velescu, A.; Clara, A.; Martí, R.; Ramos, R.; Perez-Fernandez, S.; Marcos, L.; Grau, M.; Degano, I.R.; Marrugat, J.; Elosua, R. Abnormally High Ankle-Brachial Index Is Associated with All-Cause and Cardiovascular Mortality: The REGICOR Study. *Eur. J. Vasc. Endovasc. Surg.* **2017**, *54*, 370–377. [[CrossRef](#)]
10. Gu, X.; Man, C.; Zhang, H.; Fan, Y. High ankle-brachial index and risk of cardiovascular or all-cause mortality: A meta-analysis. *Atherosclerosis* **2019**, *282*, 29–36. [[CrossRef](#)]
11. Alzamora, M.T.; Forés, R.; Torán, P.; Pera, G.; Baena-Díez, J.M.; López, B.; Sierra, M.V.; Fabregat, A. Prevalence of arterial calcification and related risk factors. The multicenter population-based ARTPER study. *Gac. Sanit.* **2012**, *26*, 74–77. [[CrossRef](#)] [[PubMed](#)]
12. Khaleghi, M.; Isseh, I.N.; Bailey, K.R.; Kullo, I.J. Family history as a risk factor for peripheral arterial disease. *Am. J. Cardiol.* **2014**, *114*, 928–932. [[CrossRef](#)] [[PubMed](#)]

13. Firnhaber, J.M.; Powell, C.S. Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. *Am. Fam. Physician* **2019**, *99*, 362–369. [[PubMed](#)]
14. Carmelli, D.; Fabsitz, R.R.; Swan, G.E.; Reed, T.; Miller, B.; Wolf, P.A. Contribution of Genetic and Environmental Influences to Ankle-Brachial Blood Pressure Index in the NHLBI Twin Study. National Heart, Lung, and Blood Institute. *Am. J. Epidemiol.* **2000**, *151*, 452–458. [[CrossRef](#)] [[PubMed](#)]
15. Wahlgren, C.M.; Magnusson, P.K.E. Genetic Influences on Peripheral Arterial Disease in a Twin Population. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, 678–682. [[CrossRef](#)] [[PubMed](#)]
16. Rutsch, F.; Nitschke, Y.; Terkeltaub, R. Genetics in Arterial Calcification: Pieces of a Puzzle and Cogs in a Wheel. *Circ. Res.* **2011**, *109*, 578–592. [[CrossRef](#)] [[PubMed](#)]
17. Wassel, C.L.; Lamina, C.; Nambi, V.; Coassin, S.; Mukamal, K.J.; Ganesh, S.K.; Jacobs, D.R.; Franceschini, N.; Papanicolaou, G.J.; Gibson, Q.; et al. Genetic Determinants of the Ankle-Brachial Index: A Meta-Analysis of a Cardiovascular Candidate Gene 50K SNP Panel in the Candidate Gene Association Resource (CARE) Consortium. *Atherosclerosis* **2012**, *222*, 138–147. [[CrossRef](#)]
18. Murabito, J.M.; White, C.C.; Kavousi, M.; Sun, Y.V.; Feitosa, M.F.; Nambi, V.; Lamina, C.; Schillert, A.; Coassin, S.; Bis, J.C.; et al. Association between Chromosome 9p21 Variants and the Ankle-Brachial Index Identified by a Meta-Analysis of 21 Genome-Wide Association Studies. *Circ. Cardiovasc. Genet.* **2012**, *5*, 100–112. [[CrossRef](#)]
19. Klarin, D.; Lynch, J.; Aragam, K.; Chaffin, M.; Assimes, T.L.; Huang, J.; Lee, K.M.; Shao, Q.; Huffman, J.E.; Natarajan, P.; et al. Genome-Wide Association Study of Peripheral Artery Disease in the Million Veteran Program. *Nat. Med.* **2019**, *25*, 1274–1279. [[CrossRef](#)]
20. Van Zuydam, N.R.; Stiby, A.; Abdalla, M.; Austin, E.; Dahlström, E.H.; McLachlan, S.; Vlachopoulou, E.; Ahlqvist, E.; Di Liao, C.; Sandholm, N.; et al. Genome-Wide Association Study of Peripheral Artery Disease. *Circ. Genom. Precis. Med.* **2021**, *14*, e002862. [[CrossRef](#)]
21. Kavousi, M.; Bos, M.M.; Barnes, H.J.; Lino Cardenas, C.L.; Wong, D.; Lu, H.; Hodonsky, C.J.; Landsmeer, L.P.L.; Turner, A.W.; Kho, M.; et al. Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification. *Nat. Genet.* **2023**, *55*, 1651–1664. [[CrossRef](#)]
22. Alzamora, M.T.; Baena-Díez, J.M.; Sorribes, M.; Forés, R.; Toran, P.; Vicheto, M.; Pera, G.; Reina, M.D.; Albaladejo, C.; Llussà, J.; et al. Peripheral Arterial Disease Study (PERART): Prevalence and Predictive Values of Asymptomatic Peripheral Arterial Occlusive Disease Related to Cardiovascular Morbidity and Mortality. *BMC Public Health* **2007**, *7*, 348. [[CrossRef](#)] [[PubMed](#)]
23. Guo, X.; Li, J.; Pang, W.; Zhao, M.; Luo, Y.; Sun, Y.; Hu, D. Sensitivity and Specificity of Ankle-Brachial Index for Detecting Angiographic Stenosis of Peripheral Arteries. *Circ. J. Off. J. Jpn. Circ. Soc.* **2008**, *72*, 605–610. [[CrossRef](#)] [[PubMed](#)]
24. Yao, S.T. Pressure Measurement in the Extremity. In *Vascular Diagnosis*; Bernstein, E.F., Ed.; Mosby: St. Louis, MI, USA, 1993; pp. 169–175. ISBN 0-8016-6557-4.
25. 1000 Genomes Project Consortium; Auton, A.; Brooks, L.D.; Durbin, R.M.; Garrison, E.P.; Kang, H.M.; Korbel, J.O.; Marchini, J.L.; McCarthy, S.; McVean, G.A.; et al. A Global Reference for Human Genetic Variation. *Nature* **2015**, *526*, 68–74. [[CrossRef](#)] [[PubMed](#)]
26. Chang, C.C.; Chow, C.C.; Tellier, L.C.; Vattikuti, S.; Purcell, S.M.; Lee, J.J. Second-Generation PLINK: Rising to the Challenge of Larger and Richer Datasets. *GigaScience* **2015**, *4*, 7. [[CrossRef](#)] [[PubMed](#)]
27. Gauderman, W.J. Sample Size Requirements for Matched Case-Control Studies of Gene-Environment Interaction. *Stat. Med.* **2002**, *21*, 35–50. [[CrossRef](#)]
28. Geisel, M.H.; Bauer, M.; Hennig, F.; Hoffmann, B.; Lehmann, N.; Möhlenkamp, S.; Kröger, K.; Kara, K.; Müller, T.; Moebus, S.; et al. Comparison of Coronary Artery Calcification, Carotid Intima-Media Thickness and Ankle-Brachial Index for Predicting 10-Year Incident Cardiovascular Events in the General Population. *Eur. Heart J.* **2017**, *38*, 1815–1822. [[CrossRef](#)]
29. Mahabadi, A.A.; Möhlenkamp, S.; Lehmann, N.; Kälsch, H.; Dykun, I.; Pundt, N.; Moebus, S.; Jöckel, K.-H.; Erbel, R. Heinz Nixdorf Recall Study Investigators CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines. *JACC Cardiovasc. Imaging* **2017**, *10*, 143–153. [[CrossRef](#)]
30. Hannou, S.A.; Wouters, K.; Paumelle, R.; Staels, B. Functional Genomics of the CDKN2A/B Locus in Cardiovascular and Metabolic Disease: What Have We Learned from GWASs? *Trends Endocrinol. Metab. TEM* **2015**, *26*, 176–184. [[CrossRef](#)]
31. Razeghian-Jahromi, I.; Karimi Akhormeh, A.; Zibaeenezhad, M.J. The Role of ANRIL in Atherosclerosis. *Dis. Markers* **2022**, *2022*, 8859677. [[CrossRef](#)]
32. Leeper, N.J.; Kullo, I.J.; Cooke, J.P. Genetics of Peripheral Artery Disease. *Circulation* **2012**, *125*, 3220–3228. [[CrossRef](#)] [[PubMed](#)]
33. Nanoudis, S.; Pikilidou, M.; Yavropoulou, M.; Zebekakis, P. The Role of MicroRNAs in Arterial Stiffness and Arterial Calcification. *Front. Genet.* **2017**, *8*, 209. [[CrossRef](#)] [[PubMed](#)]
34. Vogiatzi, G.; Oikonomou, E.; Devereux, S.; Siasos, G.; Tousoulis, D. Peripheral Artery Disease: A Micro-RNA-Related Condition? *Curr. Opin. Pharmacol.* **2018**, *39*, 105–112. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.